We are happy to announce that the miRPOC project (“miRPOC: miRNA as biomarkers in early detection and personalised treatment in ovarian cancer”) has been awarded funding under the ERA PerMed Joint Translational Call 2022, co-financed by the European Commission. This project is conducted within an international research consortium and aims to develop and validate a test based on circulating miRNA in blood serum for risk assessment, early diagnosis, and personalization of treatment for ovarian cancer. To this end, analyses will be conducted on materials from the largest prospective biobanks in Europe and the United States.

The consortium is realized in cooperation with: Cancer Registry of Norway/Oslo University Hospital (Oslo, Norway), German Cancer Research Center (Heidelberg, Germany), and Brigham and Women’s Hospital/Harvard Medical School (Boston, MA, USA). Dr. Konrad Stawiski, an oncologist-radiotherapist from the Department of Biostatistics and Translational Medicine, will lead the Polish group within the consortium.

More about the project can be read here.